MedTrace Logo

Pharmacogenomics of Paclitaxel in Ovarian Cancer

NCT00415181 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 93

Last updated 2015-01-13

No results posted yet for this study

Summary

This study will try to determine whether or not certain genes are responsible for the huge variation in toxicity and effect observed between patients treated with paclitaxel (chemotherapeutic drug). Specifically we will study this in patients with ovarian cancer who receive paclitaxel/carboplatin chemotherapy after primary surgery.

Conditions

  • Ovarian Neoplasms
  • Fallopian Tube Neoplasms

Sponsors & Collaborators

  • Danish Clinical Intervention Research Academy

    collaborator OTHER

  • Ministry of the Interior and Health, Denmark

    collaborator OTHER_GOV

  • University of Southern Denmark

    lead OTHER

Principal Investigators

  • Kim Brøsen, phd · University of Southern Denmark

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-09-30
Primary Completion
2009-01-31
Completion
2013-03-31

Countries

  • Denmark
  • Sweden

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00415181 on ClinicalTrials.gov